Recent and anticipated novel drug approvals (1Q 2025 through 4Q 2025).

IF 2.1 4区医学 Q3 PHARMACOLOGY & PHARMACY

American Journal of Health-System Pharmacy Pub Date : 2025-02-27 DOI:10.1093/ajhp/zxaf030

Matthew H Rim, Brittany L Karas, Farah Barada, Mary Golf, Vishal Prakash, Andrew M Levitsky

{"title":"Recent and anticipated novel drug approvals (1Q 2025 through 4Q 2025).","authors":"Matthew H Rim, Brittany L Karas, Farah Barada, Mary Golf, Vishal Prakash, Andrew M Levitsky","doi":"10.1093/ajhp/zxaf030","DOIUrl":null,"url":null,"abstract":"Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.Purpose: Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing updates on new and anticipated novel drug approvals.Summary: Selected drug approvals anticipated in the 12-month period covering each quarter of 2025 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from 60 novel drugs awaiting US Food and Drug Administration approval. This year's pipeline features gene and cell therapies for rare diseases, agents for neurological disorders, and several novel treatments for cancers and various disease states.Conclusion: Novel therapies continue to strengthen the current drug pipeline.","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Health-System Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ajhp/zxaf030","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

Purpose: Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing updates on new and anticipated novel drug approvals.

Summary: Selected drug approvals anticipated in the 12-month period covering each quarter of 2025 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from 60 novel drugs awaiting US Food and Drug Administration approval. This year's pipeline features gene and cell therapies for rare diseases, agents for neurological disorders, and several novel treatments for cancers and various disease states.

Conclusion: Novel therapies continue to strengthen the current drug pipeline.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Health-System Pharmacy 医学-药学

CiteScore

2.90

自引率

18.50%

发文量

341

审稿时长

3-8 weeks

期刊介绍： The American Journal of Health-System Pharmacy (AJHP) is the official publication of the American Society of Health-System Pharmacists (ASHP). It publishes peer-reviewed scientific papers on contemporary drug therapy and pharmacy practice innovations in hospitals and health systems. With a circulation of more than 43,000, AJHP is the most widely recognized and respected clinical pharmacy journal in the world.